Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs

NCT03981211 NA UNKNOWN

This study will evaluate the proportion of patients achieving confirmed SVR12 (undetectable HCV RNA at time point 12 weeks plus post treatment commencement) in patients hospitalised for IRID (injecting related infectious diseases) and commencing inpatient DAA treatment within public hospital services.

Details

Lead sponsor	Kirby Institute
Phase	NA
Status	UNKNOWN
Enrolment	60
Start date	Fri Feb 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Feb 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatitis C
• Liver Inflammation
• Liver Cirrhoses

Interventions

• Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
• Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet

Countries

Australia